tbuckley/cabot-search huggingface dataset:
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial
Authors: Suma Jacob, Jeremy Veenstra-VanderWeele, Declan Murphy, James McCracken, Janice Smith, Kevin Sanders, Christoph Meyenberg, Thomas Wiese, Gurpreet Deol-Bhullar, Christoph Wandel, Elizabeth Ashford, Evdokia Anagnostou
Journal: The Lancet Psychiatry (2022)
Double Trap Escape
Authors: Sisi Wang, Qifeng Huang, Ke Dong, Chunxia Qin, Guanghua Wen
Journal: Clinical Nuclear Medicine (2022)

Abstract A 55-year-old man was diagnosed with gastric adenocarcinoma. 18 F-FDG PET/CT was performed, which detected an enlarged nodule with increased uptake located in the omentum between the transverse colon and liver, thus lymph node metastasis was under suspicion. The patient subsequently underwent 68 Ga-FAPI PET/MRI clinical trial after signing the informed consent, which also revealed the abnormal focus with intense uptake. However, the histopathology of the nodule was unexpectedly diagnosed as fibrous hyperplasia after lymphadenectomy.
Perioperative Cerebral Infarction Secondary to Pulmonary Vein Tumor Thrombus in a Patient with Lung Myxofibrosarcoma
Authors: Rong Ma, Gui-Liang Wang, Jian-Bin Liu, Li Cai, Peng Liu, Xian-Zheng Tan
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

"Perioperative Cerebral Infarction Secondary to Pulmonary Vein Tumor Thrombus in a Patient with Lung Myxofibrosarcoma ." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp. –
Abstract 11174: Effect of APOCIII-L <sub>Rx</sub> on Lipoprotein Size and Particle Numbers Measured by NMR in Patients with Hypertriglyceridemia: Results of the AKCEA-APOCIII-L <sub>Rx</sub> Trial
Authors: Ewa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, Christie M Ballantyne, Michael D Shapiro, Patrick M Moriarty, Seth J Baum, Eric St Amour, Vickie Alexander, Shuting Xia, James D Otvos, Joseph L Witztum, Sotirios Tsimikas
Journal: Circulation (2021)

Background: APOCIII-L Rx is a hepatocyte-targeted, GalNAc-modified antisense oligonucleotide that decreases plasma levels of apoC-III and triglyceride-rich lipoproteins (TRLs). We examined the effect of APOCIII-L Rx on a variety of lipoprotein fractions measured by nuclear magnetic resonance (NMR) spectroscopy. Methods: The AKCEA-APOCIII-L Rx trial was a dose-ranging study in 114 patients with, or at risk for, ASCVD and fasting serum triglycerides 200-500 mg/dL. Patients (n=114) received AKCEA-APOCIII-L Rx (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6-12 months. Comprehensive NMR LipoProfile ® analysis was performed by LipoScience/LabCorp in frozen EDTA plasma samples collected at baseline and at the primary analysis timepoint (PAT) at 6 months. Results: Results are reported as change from baseline to PAT for the 50 mg every 4 weeks dose versus placebo. APOCIII-L Rx resulted in a significant reduction in total TRL particle (TRLP) concentration by 51% (P&lt;0.0001) with largest reductions in large-size (by 68%, P&lt;0.0001) and medium-size (by 63%, P&lt;0.0001) TRLPs. Total LDL particle (LDLP) concentration was not changed, small LDLP numerically decreased by 39% (P= 0.0713) while medium LDLP increased by 187% (P=0.0119), accompanied by an increase in average LDL size by xx 2% (p=0.0039xx). Total HDL particle (HDLP) concentration increased by 15% (P=0.0006), represented primarily by an increase in small HDL subspecies (particle diameters &lt;8.3 mm) of 32% (P=0.0008). Lower cumulative doses of APOCIII-L Rx generally reflected a dose-dependent relationship in the above parameters. Conclusion: APOCIII-L Rx results in favorable changes in lipoprotein concentration and particle size, primarily manifested by reduction in TRLs, remodeling to larger LDL particles, and increase in small HDLP. These findings suggest an improvement in overall atherogenic risk profile.
Satellite-Based Long-Term Spatiotemporal Patterns of Surface Ozone Concentrations in China: 2005–2019
Authors: Qingyang Zhu, Jianzhao Bi, Xiong Liu, Shenshen Li, Wenhao Wang, Yu Zhao, Yang Liu
Journal: Environmental Health Perspectives (2022)

Background: Although short-term ozone (O3) exposure has been associated with a series of adverse health outcomes, research on the health effects of chronic O3 exposure is still limited, especially in developing countries because of the lack of long-term exposure estimates. Objectives: The present study aimed to estimate the spatiotemporal distribution of monthly mean daily maximum 8-h average O3 concentrations in China from 2005 to 2019 at a 0.05° spatial resolution. Methods: We developed a machine learning model with a satellite-derived boundary-layer O3 column, O3 precursors, meteorological conditions, land-use information, and proxies of anthropogenic emissions as predictors. Results: The random, spatial, and temporal cross-validation R2 of our model were 0.87, 0.86, and 0.76, respectively. Model-predicted spatial distribution of ground-level O3 concentrations showed significant differences across seasons. The highest summer peak of O3 occurred in the North China Plain, whereas southern regions were the most polluted in winter. Most large urban centers showed elevated O3 levels, but their surrounding suburban areas may have even higher O3 concentrations owing to nitrogen oxides titration. The annual trend of O3 concentrations fluctuated over 2005–2013, but a significant nationwide increase was observed afterward. Discussion: The present model had enhanced performance in predicting ground-level O3 concentrations in China. This national data set of O3 concentrations would facilitate epidemiological studies to investigate the long-term health effect of O3 in China. Our results also highlight the importance of controlling O3 in China's next round of the Air Pollution Prevention and Control Action Plan. https://doi.org/10.1289/EHP9406
Advanced Tertiary Lymphoid Tissues in Protocol Biopsies in Kidney Transplant Recipients: Addressing Additional Methods To Detect Intragraft B Cells
Authors: Romy du Long, Sandrine Florquin, Jesper Kers
Journal: Journal of the American Society of Nephrology (2022)

With great interest we read the recently published article “Advanced Tertiary Lymphoid Tissues in Protocol Biopsies Are Associated with Progressive Graft Dysfunction in Kidney Transplant Recipients” by Lee et al.1 This is the first study investigating the prevalence and clinical relevance of tertiary lymphoid tissues (TLTs) in protocol biopsies in a large cohort of 214 patients with stable renal allograft function. Although this study shows interesting results about the presence of advanced TLTs in relation to progressive graft dysfunction, we have some remarks regarding the subgroup of ABO-incompatible patients of which most received a single dose of rituximab pretransplantation. According to their results, T cell dominant TLTs were detected in this subgroup, harboring far fewer B cells than TLTs in aged kidneys and kidneys with CKD based on immunofluorescence staining with CD3 and CD20. Firstly, for the reader it is unclear what the authors mean with “aged kidneys and kidneys with chronic kidney disease.” Secondly, we believe staining for intragraft B cells using only anti-CD20 antibody proposes difficulties in interpreting the results of their study. Besides depleting CD20+ B cells, it is known from the treatment of B cell non-Hodgkin lymphomas that rituximab leads to loss of expression of CD20 on B cells,2 causing false negative results. Therefore, staining with anti-CD20 antibody is not the preferred method to detect intragraft B cells. A more informative assessment would be to look for the expression of alternative B cell lineage markers, e.g., CD79a or PAX-5 as used in a previous study to detect intragraft B cells in patients treated with rituximab.3 Results on phenotypic characterization of TLTs in patients who underwent an ABO-incompatible transplantation treated with rituximab in this study based on staining with CD20 alone should be interpreted with caution and we advise using anti-CD79a antibody as an additional B cell marker to confirm the low number of intragraft B cells. Disclosures J. Kers reports consultancy with Alentis Therapeutics and Center for Human Drug Research in Leiden. All remaining authors have nothing to disclose. Funding None.
CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer
Authors: Dionisia Marie Quiroga, Ashley Pinette, Brooke Benner, Emily Schwarz, Robert Wesolowski, Andrew Stiff, Sara Zelinskas, Erin Macrae, Maryam Lustberg, Ewa Mrozek, Bhuvaneswari Ramaswamy, William E Carson
Journal: Journal of the National Comprehensive Cancer Network (2022)

"CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer" published on 31 Mar 2022 by National Comprehensive Cancer Network.
50P Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients
Authors: S. Yoon, S.M. Lim, H.A. Jung, K-P. Kim, D. Kim, H. Jeong, S. Lim, J. Kim, J. Kim, D. Patel, X. Zhao, D. Horsburgh, D.Y. Yu, J.H. Kim, S.Y. Kim, D.H. Lee
Journal: Annals of Oncology (2022)
Simultaneous visualization of multiple radionuclides in vivo
Authors: Atsushi Yagishita, Shin’ichiro Takeda, Miho Katsuragawa, Tenyo Kawamura, Hideaki Matsumura, Tadashi Orita, Izumi O. Umeda, Goro Yabu, Pietro Caradonna, Tadayuki Takahashi, Shin Watanabe, Yousuke Kanayama, Hiroshi Mizuma, Kazunobu Ohnuki, Hirofumi Fujii
Journal: Nature Biomedical Engineering (2022)
Highlights from Recent Cancer Literature
Journal: Cancer Research (2022)

Long Noncoding RNAs in Liver CancerThere is accumulating evidence that long noncoding RNAs (lncRNA), and the RNA-binding proteins (RBP) they interact with, are important regulators of tumor progression.To provide a comprehensive picture of the lncRNA landscape in cancer, Søndergaard and colleagues investigated a collection of roughly 2,300 previously identified RBPs to uncover altered RNAs in several different cancer cohorts.The authors observed increased RBP expression across tumor types and showed RBP expression had prognostic value for predicting patient survival.Knockdown of select RBPs in hepatocellular carcinoma cell lines led to the discovery of novel lncRNA-RBP pairs, such as between chaperonin complex subunit 3 (CCT3) and LINC00326, which had strong effects on the regulation of lipid metabolism and tumor progression.Expert Commentary: This study demonstrates the complexity of the lncRNA network in cancer and points towards potential diagnostic or therapeutic targets for liver cancer.(Image courtesy of
Colorectal Sessile Serrated Lesion Detection Using Linked Color Imaging: A Multicenter, Parallel Randomized Controlled Trial
Authors: Jun Li, Di Zhang, Yunlei Wei, Kan Chen, Ruijin Wu, Kangsheng Peng, Xiaojia Hou, Lei Li, Chao Huang, Yuxin Wang, Linjuan Xun, Hongwei Xu, Jianhua Wang, Zhirong Chen, Ming Shen, Feng Liu
Journal: Clinical Gastroenterology and Hepatology (2022)
Template‐Enabled Biofabrication of Thick 3D Tissues with Patterned Perfusable Macrochannels (Adv. Healthcare Mater. 7/2022)
Authors: Elham Davoodi, Hossein Montazerian, Masoud Zhianmanesh, Reza Abbasgholizadeh, Reihaneh Haghniaz, Avijit Baidya, Homeyra Pourmohammadali, Nasim Annabi, Paul S. Weiss, Ehsan Toyserkani, Ali Khademhosseini
Journal: Advanced Healthcare Materials (2022)
Targeting <i>HER2</i>-Mutant NSCLC — The Light Is On
Authors: Antonio Passaro, Solange Peters
Journal: New England Journal of Medicine (2022)

The identification of human epidermal growth factor receptor 2 (HER2, also known as ErbB2 or HER2/neu) generated high expectations for the treatment of different cancers carrying HER2 aberrations, including non–small-cell lung cancer (NSCLC).1 Across cancer types, HER2 mutations and amplification and HER2 overexpression represent biologically distinct alterations that can harbor driver oncogenic properties. HER2 amplification is recognized as a frequent molecular abnormality and therapeutic target in breast and gastric cancer.1 The development of HER2 inhibition for the treatment of lung cancer was inspired by the successful therapeutic history of targeting HER2 amplification in breast cancer and focused initially on HER2 . . .
In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 d
Authors: Darren Lau, Lynora Saxinger
Journal: Annals of Internal Medicine (2022)

ACP Journal ClubJanuary 2022In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 dDarren Lau, MD, PhD, Lynora Saxinger, MDDarren Lau, MD, PhDUniversity of Alberta, Edmonton, Alberta, Canada (D.L., L.S.)Search for more papers by this author, Lynora Saxinger, MDUniversity of Alberta, Edmonton, Alberta, Canada (D.L., L.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J21-0008 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationO’Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385:1184-95. https://pubmed.ncbi.nlm.nih.gov/34347950Clinical Impact RatingsGIM/FP/GP: Public Health: Reference1. Regeneron Pharmaceuticals. Regeneron announces new U.S. government agreement to purchase additional doses of REGEN-COV (casirivimab and imdevimab) antibody cocktail. 14 Sep 2021. Accessed at https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-new-us-government-agreement-purchase on 14 Oct 2021. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Alberta, Edmonton, Alberta, Canada (D.L., L.S.)Disclosures: The commentators have reported no disclosures of interest. The forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J21-0008.This article was published at Annals.org on 4 January 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics January 2022Volume 175, Issue 1Page: JC5KeywordsCOVID-19DisclosureHospitalizationsMonoclonal antibodiesPolymerase chain reactionPostexposure prophylaxisProphylaxisSigns and symptomsSubcutaneous injectionsVaccines ePublished: 4 January 2022 Issue Published: January 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
<i>Txnip</i> Enhances Fitness of <i>Dnmt3a</i>-Mutant Hematopoietic Stem Cells via <i>p21</i>
Authors: Christine R. Zhang, Elizabeth L. Ostrander, Ostap Kukhar, Cates Mallaney, Jiameng Sun, Emily Haussler, Hamza Celik, Won Kyun Koh, Katherine Y. King, Paul Gontarz, Grant A. Challen
Journal: Blood Cancer Discovery (2022)

Clonal hematopoiesis (CH) refers to the age-related expansion of specific clones in the blood system, and manifests from somatic mutations acquired in hematopoietic stem cells (HSCs). Most CH variants occur in the gene DNMT3A, but while DNMT3A-mutant CH becomes almost ubiquitous in aging humans, a unifying molecular mechanism to illuminate how DNMT3A-mutant HSCs outcompete their counterparts is lacking. Here, we used interferon gamma (IFNγ) as a model to study the mechanisms by which Dnmt3a mutations increase HSC fitness under hematopoietic stress. We found Dnmt3a-mutant HSCs resist IFNγ-mediated depletion, and IFNγ-signaling is required for clonal expansion of Dnmt3a-mutant HSCs in vivo. Mechanistically, DNA hypomethylation-associated overexpression of Txnip in Dnmt3a-mutant HSCs leads to p53 stabilization and upregulation of p21. This preserves the functional potential of Dnmt3a-mutant HSCs through increased quiescence and resistance to IFNγ-induced apoptosis. These data identify a previously undescribed mechanism to explain increased fitness of DNMT3A-mutant clones under hematopoietic stress.DNMT3A mutations are common variants in clonal hematopoiesis, and recurrent events in blood cancers. Yet the mechanisms by which these mutations provide hematopoietic stem cells a competitive advantage as a precursor to malignant transformation remain unclear. Here, we use inflammatory stress to uncover molecular mechanisms leading to this fitness advantage.See related commentary by De Dominici and DeGregori, p. 178. This article is highlighted in the In This Issue feature, p. 171.
68Ga-PSMA Uptake in Brain Metastasis of Gastric Carcinoma
Authors: Selin Kesim, Kevser Oksuzoglu
Journal: Clinical Nuclear Medicine (2022)

Abstract A 69-year-old man with a known history of gastric and prostate adenocarcinoma was referred to 68 Ga–prostate-specific membrane antigen (PSMA) PET/CT for restaging due to biochemical recurrence of prostate cancer. 68 Ga-PSMA PET/CT revealed tracer accumulation in the primary prostatic lesion, lymph node, bone metastases, and brain lesion, which was later confirmed on biopsy to be metastasis of gastric carcinoma. This case reminds us of the variable spectrum of 68 Ga-PSMA uptake in prostatic and nonprostatic metastatic lesions, the potential pitfalls on PET/CT images in the workup of patients with concomitant malignancies.
Exchanging humpty dumpties is not a solution: Why a representational view of knowledge must be replaced with an action-based approach
Authors: Jeremy I. M. Carpendale, Charlie Lewis
Journal: Behavioral and Brain Sciences (2021)

Abstract In arguing for knowledge representation before belief, Phillips et al. presuppose a representational theory of knowledge, a view that has been extensively criticized. As an alternative, we propose an action-based approach to knowledge, conceptualized in terms of skill. We outline the implications of this approach for children's developing social understanding, beginning with sensorimotor interaction and extending to the verbal level.
A Wearable Tele-Health System towards Monitoring COVID-19 and Chronic Diseases
Authors: Wei Jiang, Sumit Majumder, Samarth Kumar, Sophini Subramaniam, Xiaohe Li, Ridha Khedri, Tapas Mondal, Mansour Abolghasemian, Imran Satia, M. Jamal Deen
Journal: IEEE Reviews in Biomedical Engineering (2021)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic since early 2020. The coronavirus disease 2019 (COVID-19) has already caused more than three million deaths worldwide and affected people's physical and mental health. COVID-19 patients with mild symptoms are generally required to self-isolate and monitor for symptoms at least for 14 days in the case the disease turns towards severe complications. In this work, we overviewed the impact of COVID-19 on the patients' general health with a focus on their cardiovascular, respiratory and mental health, and investigated several existing patient monitoring systems. We addressed the limitations of these systems and proposed a wearable telehealth solution for monitoring a set of physiological parameters that are critical for COVID-19 patients such as body temperature, heart rate, heart rate variability, blood oxygen saturation, respiratory rate, blood pressure, and cough. This physiological information can be further combined to potentially estimate the lung function using artificial intelligence (AI) and sensor fusion techniques. The prototype, which includes the hardware and a smartphone app, showed promising results with performance comparable to or better than similar commercial devices, thus potentially making the proposed system an ideal wearable solution for long-term monitoring of COVID-19 patients and other chronic diseases.
End the Ban: A Military Doctor's Perspective
Authors: Joseph M. Maciuba
Journal: Annals of Internal Medicine (2022)

On Being a DoctorApril 2022End the Ban: A Military Doctor's PerspectiveJoseph M. Maciuba, MDJoseph M. Maciuba, MDWalter Reed National Military Medical Center, Bethesda, MarylandSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M21-4767 Audio Reading - “End the Ban: A Military Doctor's Perspective” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “End the Ban: A Military Doctor's Perspective” by Joseph M. Maciuba, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail As a deployed Army doctor, I provided medical care at a clinic overseas. One of my duties was to plan for an emergency walking blood bank in which we would draw whole blood from healthy donors to transfuse into trauma patients in real time. In preparation, my team and I prescreened individuals for donation and trained for a mass casualty event.One day, one of the surgeons told me that a severely wounded patient was inbound to the hospital. The patient had already received 12 units of blood on the battlefield. Upon arrival, he was taken immediately to the operating ... Author, Article, and Disclosure InformationAffiliations: Walter Reed National Military Medical Center, Bethesda, MarylandDisclaimer: The views expressed in this essay are those of the author and do not reflect the official policy of the Department of the Army, Department of Defense, or U.S. government.Corresponding Author: Joseph M. Maciuba, MD, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889; e-mail, joseph.m.maciuba.[email protected]mil. PreviousarticleNextarticle Advertisement Audio Reading - “End the Ban: A Military Doctor's Perspective” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “End the Ban: A Military Doctor's Perspective” by Joseph M. Maciuba, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics April 2022Volume 175, Issue 4Page: 608-609 ePublished: 19 April 2022 Issue Published: April 2022 PDF downloadLoading ...
Genetic Lineage Tracing of Pericardial Cavity Macrophages in the Injured Heart
Authors: Hengwei Jin, Kuo Liu, Xiuzhen Huang, Huanhuan Huo, Jialing Mou, Zengyong Qiao, Ben He, Bin Zhou
Journal: Circulation Research (2022)

Background: Macrophages play an important role in cardiac repair after myocardial infarction (MI). In addition to the resident macrophages and blood-derived monocytes, Gata6 + cavity macrophages located in the pericardial space were recently reported to relocate to the injured myocardium and prevent cardiac fibrosis. However, there is no direct genetic evidence to support it. Methods: We used dual recombinases (Cre and Dre) to specifically label Gata6 + pericardial macrophages (GPCMs) in vivo. For functional study, we generated genetic systems to specifically ablate GPCMs by induced expression of DTR (diphtheria toxin receptor) or knockout of Gata6 (GATA binding protein 6) gene in GPCMs. We used these genetic systems to study GPCMs in pericardium intact MI model. Results: Dual recombinases-mediated genetic system targeted GPCMs specifically and efficiently. Lineage tracing study revealed accumulation of GPCMs on the surface of MI heart without deep penetration into the myocardium. We did not detect significant change of cardiac fibrosis or function of MI hearts after cell ablation or Gata6 knockout in GPCMs. Conclusions: GPCMs minimally invade the injured heart after MI. Nor do they prevent cardiac fibrosis and exhibit reparative function on injured heart. This study also underlines the importance of using specific genetic tool for studying in vivo cell fates and functions.